European committee takes a second look at Alzheimer's drug and …
1 day ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.
Ticker: Biogen Alzheimer's drug gets second look in EU; Ford …
1 day ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...
EU regulator backs Eisai-Biogen Alzheimer's drug after initial ...
1 day ago · The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four ...
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen to shut down controversial Alzheimer's drug Aduhelm | AP News
Jan 31, 2024 · Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will end a study of the drug needed for …
Biogen’s Decision to Discontinue Alzheimer’s Drug | alz.org
CHICAGO, Jan. 31, 2024 — Despite today’s announcement from Biogen, the Alzheimer’s Association is extremely optimistic about the future of Alzheimer’s treatments; a new era that started with the Food and Drug Administration (FDA) accelerated approval of Aduhelm in 2021.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Biogen to stop selling controversial Alzheimer's drug Aduhelm - NBC News
Jan 31, 2024 · Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.
Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter
Jan 31, 2024 · Biogen will end a post-approval study of Alzheimer's treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs of obtaining standard...
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb ... - Biogen
Jul 6, 2023 · “Today, the FDA approved LEQEMBI under the traditional approval pathway, making LEQEMBI the first and only approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease.